{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:15:23Z","timestamp":1774527323476,"version":"3.50.1"},"reference-count":63,"publisher":"Wiley","issue":"S6","license":[{"start":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T00:00:00Z","timestamp":1479686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Although there is presently no cure for rosacea, there are several recommended treatment options available to control many of the symptoms and to prevent them from getting worse. In addition to self\u2010help measures like avoidance of trigger factors and proper skin care, rosacea management should include topical medications as one of the first\u2010line choices for patients with erythematous and mild to severe papulopustular rosacea. Since mixed forms of characteristic rosacea symptoms are more common, medical treatment must be symptom\u2010tailored for each individual case and will often involve a combination therapy. Approved topical agents for the major symptoms of rosacea encompass brimonidine for erythema and ivermectin, metronidazole or azelaic acid for inflammatory lesions, all of which have shown their efficacy in numerous valid, well\u2010controlled trials. In addition, there are several other, not approved topical treatments which are possible options that require further validation in larger well\u2010controlled studies.<\/jats:p>","DOI":"10.1111\/ddg.13143","type":"journal-article","created":{"date-parts":[[2016,11,21]],"date-time":"2016-11-21T12:55:39Z","timestamp":1479732939000},"page":"17-27","source":"Crossref","is-referenced-by-count":27,"title":["Rosacea Management: Update on general measures and topical treatment options"],"prefix":"10.1111","volume":"14","author":[{"given":"M","family":"Schaller","sequence":"first","affiliation":[{"name":"Department of Dermatology T\u00fcbingen University Hospital T\u00fcbingen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Sch\u00f6fer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology, and Allergology University Hospital Goethe\u2010University Frankfurt\/M Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Homey","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical Faculty University of D\u00fcsseldorf D\u00fcsseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Hofmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology Charit\u00e9 \u2010 Universit\u00e4tsmedizin Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Gieler","sequence":"additional","affiliation":[{"name":"Clinics for Dermatology and Allergology Justus\u2010Liebig\u2010University Giessen Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology HELIOS Hospital Wuppertal, Witten\/Herdecke University Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TA","family":"Luger","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital M\u00fcnster Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Ruzicka","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergology Ludwig\u2010Maximilian University Munich Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Steinhoff","sequence":"additional","affiliation":[{"name":"Department of Dermatology and UCD Charles Institute for Translational Dermatology University College Dublin Dublin Ireland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,21]]},"reference":[{"key":"e_1_2_19_2_1","first-page":"234","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care","volume":"92","author":"Del Rosso JQ","year":"2013","journal-title":"Cutis"},{"key":"e_1_2_19_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.01.048"},{"key":"e_1_2_19_4_1","first-page":"159","article-title":"Update on the management of rosacea","volume":"8","author":"Weinkle AP","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"e_1_2_19_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.045"},{"key":"e_1_2_19_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.12101_suppl"},{"key":"e_1_2_19_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.08.027"},{"issue":"6","key":"e_1_2_19_8_1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/ddg.13139","article-title":"Pathogenesis and clinical presentation of rosacea as a key for a symptom\u2010ori\u00adented therapy","volume":"14","author":"Reinholz M","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_19_9_1","first-page":"16","article-title":"Korneotherapeutische Hautpflege bei Rosacea","volume":"3","author":"Lautenschl\u00e4ger H","year":"2010","journal-title":"Aesthetische Dermatologie"},{"key":"e_1_2_19_10_1","first-page":"26","article-title":"Rosacea, Reactive Oxygen Species, and Azelaic Acid","volume":"2","author":"Jones D","year":"2009","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_19_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-013-0394-4"},{"key":"e_1_2_19_12_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1312933110"},{"key":"e_1_2_19_13_1","first-page":"277","article-title":"Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents","volume":"92","author":"Del Rosso JQ","year":"2013","journal-title":"Cutis"},{"key":"e_1_2_19_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003262.pub5"},{"key":"e_1_2_19_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03751.x"},{"issue":"6","key":"e_1_2_19_16_1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/ddg.13141","article-title":"State of the art: Systemic rosacea management","volume":"14","author":"Schaller M","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_2_19_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2011.10716.x"},{"key":"e_1_2_19_18_1","first-page":"650","article-title":"Efficacy and safety of once\u2010daily topical brimonidine tartrate gel 0.5 % for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double\u2010blind, and vehicle\u2010controlled pivotal studies","volume":"12","author":"Fowler J","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_19_1","first-page":"56","article-title":"Long\u2010term safety and efficacy of once\u2010daily topical brimonidine tartrate gel 0.5 % for the treatment of moderate to severe facial erythema of rosacea: results of a 1\u2010year open\u2010label study","volume":"13","author":"Moore A","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2014.04.002"},{"key":"e_1_2_19_21_1","first-page":"33","article-title":"Optimizing the use of topical brimonidine in rosacea management: panel recommendations","volume":"14","author":"Tanghetti EA","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.036"},{"key":"e_1_2_19_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.010"},{"key":"e_1_2_19_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13305"},{"key":"e_1_2_19_25_1","first-page":"316","article-title":"Efficacy and safety of ivermectin 1 % cream in treatment of papulopustular rosacea: results of two randomized, double\u2010blind, vehicle\u2010controlled pivotal studies","volume":"13","author":"Stein Gold L","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2009.00684.x"},{"key":"e_1_2_19_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(01)00403-4"},{"key":"e_1_2_19_28_1","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0022-3565(24)35272-3","article-title":"Anti\u2010 inflammatory activity of macrolide antibiotics","volume":"292","author":"Ianaro A","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_19_29_1","first-page":"1380","article-title":"Ivermectin Phase 3 Study Group. Long\u2010term safety of ivermectin 1 % cream vs azelaic acid 15 % gel in treating inflammatory lesions of rosacea: results of two 40\u2010week controlled, investigator\u2010blinded trials","volume":"13","author":"Stein Gold L","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13408"},{"key":"e_1_2_19_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13537"},{"key":"e_1_2_19_32_1","first-page":"317","article-title":"Metronidazole in the treatment of rosacea: do formulation, dosing, and concentration matter","volume":"5","author":"Yoo J","year":"2006","journal-title":"J Drugs Dermatol."},{"key":"e_1_2_19_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70085-X"},{"issue":"4","key":"e_1_2_19_34_1","first-page":"3","article-title":"Efficacy and safety of once\u2010daily metronidazole 1 % gel compared with twice\u2010daily azelaic acid 15 % gel in the treatment of rosacea","volume":"77","author":"Wolf JE","year":"2006","journal-title":"Cutis"},{"key":"e_1_2_19_35_1","first-page":"101","article-title":"Update on the management of rosacea: a status report on the current role and new horizons with topical azelaic acid","volume":"13","author":"Del Rosso JQ","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_36_1","first-page":"306","article-title":"Azelaic acid foam 15 % in the treatment of papulopustular rosacea: a randomized, double\u2010blind, vehicle\u2010controlled study","volume":"92","author":"Draelos ZD","year":"2013","journal-title":"Cutis"},{"key":"e_1_2_19_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2005.02769.x"},{"key":"e_1_2_19_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2010.07466.x"},{"key":"e_1_2_19_39_1","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2003.308"},{"key":"e_1_2_19_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/000155599750009906"},{"key":"e_1_2_19_41_1","first-page":"177","article-title":"A pilot study of 5 percent permethrin cream versus 0.75 percent metronidazole gel in acne rosacea","volume":"56","author":"Signore R","year":"1995","journal-title":"Cutis"},{"key":"e_1_2_19_42_1","doi-asserted-by":"publisher","DOI":"10.1159\/000065849"},{"key":"e_1_2_19_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2009.09.006"},{"key":"e_1_2_19_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02125.x"},{"key":"e_1_2_19_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.03.033"},{"key":"e_1_2_19_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03167.x"},{"key":"e_1_2_19_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2004.02130.x"},{"key":"e_1_2_19_48_1","doi-asserted-by":"publisher","DOI":"10.1159\/000051380"},{"key":"e_1_2_19_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2011.01223.x"},{"key":"e_1_2_19_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(03)02157-1"},{"key":"e_1_2_19_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03427.x"},{"key":"e_1_2_19_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2008.02589.x"},{"key":"e_1_2_19_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2006.07669.x"},{"key":"e_1_2_19_54_1","doi-asserted-by":"crossref","first-page":"pii","DOI":"10.5070\/D3215027532","article-title":"Rosacea\u2010like eruption due to topical pimecrolimus","volume":"21","author":"El\u2010Heis S","year":"2015","journal-title":"Dermatol online J"},{"key":"e_1_2_19_55_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.134.6.679"},{"key":"e_1_2_19_56_1","first-page":"639","article-title":"A multicenter study of topical azelaic acid 15 % gel in combination with oral doxycycline as initial therapy and azelaic acid 15 % gel as maintenance monotherapy","volume":"8","author":"Thiboutot DM","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_19_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12419"},{"key":"e_1_2_19_58_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-009-0037-2"},{"issue":"3","key":"e_1_2_19_59_1","first-page":"544","article-title":"Treatment of ocular rosacea: comparative study of topical cyclosporine and oral doxycycline","volume":"8","author":"Arman A","year":"2015","journal-title":"Int J Ophthalmol"},{"key":"e_1_2_19_60_1","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2006.22.47"},{"key":"e_1_2_19_61_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000176611.88579.0a"},{"key":"e_1_2_19_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181cda38f"},{"key":"e_1_2_19_63_1","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0b013e3181ca38a0"},{"key":"e_1_2_19_64_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2013.801991"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.13143","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fddg.13143","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.13143","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T19:42:56Z","timestamp":1749757376000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.13143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,21]]},"references-count":63,"journal-issue":{"issue":"S6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1111\/ddg.13143"],"URL":"https:\/\/doi.org\/10.1111\/ddg.13143","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,21]]}}}